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Mutations in the uromodulin gene decrease urinary excretion
of Tamm-Horsfall protein.
Background. Mutations in the uromodulin (UMOD)
gene that encodes Tamm-Horsfall protein (THP) cause an
autosomal-dominant form of chronic renal failure. We have now
investigated effects of UMOD gene mutations on protein ex-
pression by quantitatively measuring THP excretion.
Methods. THP excretion was determined by enzyme-linked
immunosorbent assay (ELISA) of urine collections obtained
from 16 related individuals with a 27 bp deletion in the UMOD
gene and seven individuals with other UMOD mutations. THP
excretion of 22 control subjects (18 genetically related individ-
uals and four spouses in the UMOD deletion family) was also
determined.
Results. The 16 individuals carrying the deletion mutation ex-
creted 5.8 ± 6.3 mg THP/g creatinine into their urine. The 18
unaffected relatives from the same family excreted 40.8 ±9.7 mg
THP/g creatinine (P < 0.0001) and the four spouses excreted
43.9 ± 25.1 mg THP/g creatinine (P < 0.0001 vs. individuals
with the deletion mutation). THP excretion of sevem individu-
als with other UMOD gene mutations was also extremely low
(range of 0.14 to 5.9 mg THP/g creatinine). All individuals with
UMOD mutations had low THP excretion, irrespective of gen-
der, glomerular filtration rate (GFR), or age.
Conclusion. These studies quantitatively show that the
autosomal-dominant gene mutations responsible for UMOD-
associated kidney disease cause a profound reduction of THP
excretion. We speculate that this suppression of normal THP
excretion reflects deleterious effects of mutated THP within
the kidney. Such effects may also play an important role in the
pathogenesis of the progressive renal failure observed in pa-
tients with UMOD gene mutations.
The clinical condition known as either familial juvenile
hyperuricemic nephropathy (FJHN) or medullary cys-
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tic kidney disease type 2 (MCKD 2) or as uromodulin
(UMOD)-associated kidney disease leads to precocious
gout and progressive chronic renal failure. Genetic analy-
sis has recently shown that mutations in the UMOD gene
that encodes Tamm-Horsfall protein (THP) result in this
autosomal-dominant condition [1–5].
THP is produced exclusively in the thick ascending
limb of Henle’s loop (TAL) and early distal convoluted
tubule [6]. This surface membrane protein is the most
abundant protein in normal urine [7]. Urinary THP ex-
cretion has been evaluated by either 24-hour excretion
[7–9] or in relation to creatinine excretion [9, 10]. Urinary
THP decreases with declining glomerular filtration rate
(GFR) [9, 10]. Since the ratio of urinary THP to creatinine
is stable after 4 years of age [10], the THP excretion of
adults and children can be compared. Although THP had
been initially described nearly 4 decades earlier [11], the
nucleotide sequence encoding THP was determined dur-
ing investigations of a subspecies of this protein isolated
from the urine of pregnant women. Since this protein had
been called uromodulin [12], the nucleotide sequence was
designated as the UMOD gene.
In the present studies, we have investigated the effect
of mutations in the UMOD gene on protein expression
by quantitatively determining THP excretion. A sensi-
tive enzyme-linked immunosorbent assay (ELISA) was
used to measure the excretion of THP by members of
an extended family that share a deletion in the UMOD
gene, unaffected individuals in this family, and a smaller
number of patients with other mutations of the UMOD
gene.
METHODS
All participants provided informed consent to a study
protocol approved by the Institutional Review Board
of Wake Forest University School of Medicine. Urine
and blood samples were obtained from individuals from
five families with known disease-associated mutations in
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Table 1. Features of families with mutations in the gene that encodes Tamm-Horsfall protein (THP)
Age Serum Urinary THP/ Urinary THP
Family Mutation years creatinine creatinine ratio mg/24 hours
1 (N = 16) g.1966 1922deletion 37.9 ± 14.2 1.85 ± 0.93 6.0 ± 6.1 5.5 ± 5.3
2 g.1990C>G 16.4 1.3 2.5 6.5
35.5 2.2 0.56 0.53
3 g.1880G>A 10.9 0.8 5.9 3.0
23.6 2.0 4.4 4.5
35.7 2.2 0.14 0.11
4 g.2086T>C 17.0 1.1 5.6 3.2
5 g.2105G>A 51.0 2.0 1.3 1.3
1 (unaffected) 29.2 ± 17.2 0.95 ± 0.13 40.8 ± 9.7a 43.8 ± 27.9a
(N = 18) (N = 17) (N = 18) (N = 18)b
1 (spouses) (N = 4) 47.5 ± 8.3 1.05 ± 0.17 43.9 ± 25.1a 55.4 ± 36.8a
aP < 0.0001 vs. family 1 with deletion mutation.
bRange of 21 to 119 mg THP/24 hours.
the UMOD gene. They collected 24-hour urinary sam-
ples while on an ad libitum diet. Each urine sample
was preserved with 1 mg/mL thimerosal (Sigma-Aldrich,
St. Louis, MO, USA) and 0.02% sodium azide (Fisher
Scientific, Hampton, NH, USA). Serum samples for uric
acid and creatinine were also obtained.
The creatinine measurements were performed by the
Jaffe´ alkaline picrate kinetic method [13]. The uric acid
measurements were performed on the ADVIA 1650
Chemistry System (Bayer Diagnostics, Tarrytown, NY,
USA). This uric acid method is based on the Fossati enzy-
matic reaction using uricase with a Trinder-like end point
[14].
Genetic studies
Peripheral venous blood samples were obtained by
standard venipuncture and genomic DNA was isolated
using the QIAmp blood kit (Qiagen, Valencia, CA,
USA). Polymerase chain reaction (PCR) amplification of
the UMOD gene was performed using oligonucleotide
primers [1]. Amplified DNA was purified with the QI-
Aquick PCR Purification Kit (Qiagen) and was se-
quenced using the BigDye Terminator Cycle Sequencing
Kit on an ABI 3700 DNA Analyzer (Applied Biosystems,
Foster City, CA, USA) by the Genomics and Proteomics
Core Laboratories of the University of Pittsburgh. Se-
quence analysis was performed with Sequencher 4.1 soft-
ware (GeneCodes, Ann Arbor, MI, USA).
Immunoassay
The ELISA for THP was performed using a general
protocol previously described in detail for human uri-
nary osteopontin [15, 16] with the following modifica-
tions for THP. Urine samples were diluted with a 0.01
mol/L PO4, pH 9.3, buffer prior to coating of 96-well Max-
isorb microtiter plates (Nunc, Rochester, NY, USA) us-
ing a series of twofold dilutions after an initial dilution of
urine at 1:100 or 1:400. The primary antibody was a poly-
clonal rabbit anti-THP prepared as previously described
[17], and the secondary antibody was an affinity purified
peroxidase-conjugated goat antirabbit IgG (Jackson Im-
munoResearch, West Grove, PA, USA). Concentrations
of THP in samples were calculated using the curve de-
rived from the optical densities of THP standards run on
the same plate. The THP level of the urine sample from
one subject was below the detection limit for the assay
(∼1 ng/mL after dilution) and was assigned a value of
0.01 lg/mL for calculations and graphing. All results of
groups are expressed as mean ± 1 SD. Potential differ-
ences between groups were evaluated by the unpaired
Student t test.
RESULTS
Urine and blood samples were obtained from the
45 individuals listed in Table 1. Gene sequence analy-
sis showed that 16 individuals from a very large fam-
ily (family 1) had a 27 bp deletion (g.1966 1922del) in
exon 4 of the UMOD gene. The clinical characteristics
of this family have been extensively described [18]. The
affected individuals from four additional families had sin-
gle nucleotide mutations in exon 4 of the UMOD gene
as follows: three individuals had a g.1990C>G mutation
(family 2), two individuals had a g.1880G>A mutation
(family 3), one individual had a g.2086T>C mutation [1]
(family 4), and one individual had a g.2105G>A muta-
tion (family 5). Sequence analysis of the 18 additional
genetically related individuals in family 1 in the present
study revealed no mutations in exon 4 of the UMOD gene.
Analysis of samples from four genetically unrelated fam-
ily 1 spouses provided additional control observations.
The urinary THP excretion of affected members of
family 1 was markedly lower than that of unaffected fam-
ily members (Table 1). The difference between groups
within this kindred was highly significant (P < 0.0001)
for comparisons of either the ratio of milligram THP to
gram urinary creatinine or milligram THP per 24 hours.
Differences in the level of THP excretion by affected
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Fig. 1. Comparison of urinary Tamm-Horsfall protein
(THP)/creatinine ratios to the serum creatinine levels of indi-
viduals with a mutation in the gene encoding THP in family 1 and in
families 2 to 5 with values of the unaffected individuals in family 1 and
family 1 spouses.
80
60
40
20
0U
rin
ar
y 
TH
P/
cr
ea
tin
in
e 
ra
tio
0 10 20 30 40 50 60 70
Age, years
Fig. 2. Comparison of urinary Tamm-Horsfall protein
(THP)/creatinine ratios to the age of the individuals in the same groups
as in Figure 1 using the same set of symbols.
individuals and the spouses in family 1 were also highly
significant (P < 0.0001 for both comparisons).
Many affected members of family 1 had higher serum
creatinine levels, a finding consistent with their under-
lying disorder. The GFR of patients with UMOD gene
mutations usually begins to decline in the late teens.
THP excretion of affected individuals was lowest at high
serum creatinine levels (Fig. 1). However, it is notewor-
thy that the three affected family 1 members with the
lowest serum creatinine levels (0.8 mg/dL) (the GFR es-
timated for these three individuals using the four variable
modified MDRD equation [abstract; Levey AS et al, J
Am Soc Nephrol 11:155A, 2000] was 98 ± 6.0 mL/min/
1.73 m2) had very low THP excretion in compari-
son to that of unaffected family members. The urinary
THP/creatinine ratio for these three individuals was
15.3 ± 2.3 (P = 0.0003 vs. the 18 unaffected family
members). The relationship of THP excretion to age is
shown in Figure 2. Affected individuals had low urinary
THP/creatinine ratios at all ages.
DISCUSSION
All 16 members of family 1 sharing a UMOD gene
mutation had lower urinary excretion of THP than any
family members without the mutation (Figs. 1 and 2)
(Table 1). The urinary excretion of THP was low, even
at the earliest ages before developing chronic renal fail-
ure. Very low urinary THP excretion was also observed
in all seven individuals with other mutations in exon 4 of
the UMOD gene (Table 1) (Figs. 1 and 2) regardless of
age, gender, or level of renal function.
The present quantitative evidence for markedly de-
creased THP excretion by patients with mutations in
exon 4 of the UMOD gene is consistent with and ex-
tends recent reports [4, 19]. These studies described
decreased THP on Western blots of urine from a small
number of patients with single nucleotide mutations of
the UMOD gene [4, 19]. Decreased THP excretion ap-
pears to be a general feature of chronic renal failure [9,
10]. However, Dahan et al [4] recently reported that THP
detected on Western blots of urine from patients with cre-
atinine clearances less than 40 mL/min was decreased in
patients with UMOD mutations when compared to THP
of patients with other causes of renal failure. Our studies
early in the disease provide additional evidence that re-
nal failure is not the primary factor causing the markedly
decreased THP excretion by patients with UMOD
mutations.
A precise correlation of markedly decreased THP ex-
cretion with UMOD mutations detected by genetic test-
ing was demonstrated in the present study. This suggests
that, in the future, tests of THP excretion may provide a
noninvasive way to clinically evaluate young children in
families with known UMOD mutations. However, DNA
testing is now available (Athena Diagnostics, Worcester,
MA, USA), while measurements of THP excretion are
now performed only in a research setting. Thus, deter-
mining THP excretion is not currently a practical screen-
ing test for the relatively small number of individuals in
families with this disease.
The 616 amino acid sequence of normal THP con-
tains an abundance of domains with an extremely high
cysteine content. Such cysteine residues are believed to
be important determinants of the quaternary structure
of normal THP via intrachain disulfide bonds [20]. It is
thus noteworthy that most of the described mutations in
the UMOD gene have occurred in the exons encoding
cysteine-rich domains. Indeed, most of these mutations
have involved a cysteine substitution [1]. The formation
of disulfide bonds in the endoplasmic reticulum may be
critical for the subsequent export of THP from TAL cells
[21]. This concept is supported by the recent observation
of THP deposits in the endoplasmic reticulum in TAL
cells in kidneys of individuals with UMOD gene muta-
tions [4, 19].
Bleyer et al: Mutations decrease Tamm-Horsfall protein excretion 977
Our studies expand the types of UMOD gene muta-
tions influencing THP excretion by showing that not only
missense mutations, but also deletions markedly decrease
THP excretion. The mutation in family 1 (g.1966 1922del)
causes deletion of 9 amino acids from the THP peptide
sequence. Single copy mutations that completely block
production of a protein (null mutation) would not be ex-
pected to influence secretion of the protein encoded by
the other (normal) allele. Thus, a null mutation of the
UMOD gene would be expected to reduce THP excre-
tion to half of normal. However, our quantitative studies
of individuals with this deletion mutation showed that
levels of excretion were much less than half the amount
of THP excreted by their unaffected relatives. Therefore,
it is likely that excretion of normal THP molecules is
suppressed by presence of the mutated protein. Since the
decrease of THP excretion occurs early when the GFR is
normal, the decreased THP excretion is not simply due
to renal failure.
The production of a mutated protein in this disease
may have deleterious effects within the kidney that are
analogous to effects found as a consequence of dominant
interference caused by mutations in other diseases such as
ataxia telangiectasia [22] and pseudoachondroplasia [23].
UMOD-associated kidney disease appears to be one of
a growing number of endoplasmic reticulum storage dis-
eases, in which an abnormal protein precipitates in the en-
doplasmic reticulum with deleterious consequences [24].
We speculate that such effects play an important role in
the pathogenesis of the progressive renal failure observed
in patients with UMOD gene mutations.
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